ArticleGynecologic oncology2018
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
Article in Gynecologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 7 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.Gynecologic oncology · 2024Pooled it
- Meta-analysis of the clinicopathologic features of endometrial cancer molecular staging.Frontiers in oncology · 2024Pooled it
- Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis.Archives of gynecology and obstetrics · 2022Pooled it
- TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma.Pathology oncology research : POR · 2020Pooled it
- TCGA Molecular Subgroups in Endometrial Undifferentiated/Dedifferentiated Carcinoma.Pathology oncology research : POR · 2020Pooled it
- Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups.Archives of gynecology and obstetrics · 2020Pooled it
- Current status and targeted therapies in endometrial cancer: Molecular classification-driven treatment strategies (Review).Oncology letters · 2026Review
- Promising survival prospects and immunotherapy potential in polymerase epsilon-mutated endometrial cancer: a comprehensive systematic review and meta-analysis unveiling future therapeutic opportunities.Obstetrics & gynecology science · 2026Article
- Prognostic Impact of POLE Exonuclease-Domain Mutations in Endometrial Cancer: A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Article
- The relationship between histopathological data and molecular alterations with oncological outcomes in endometrioid-type endometrial cancers and a novel POLE mutation.Journal of gynecologic oncology · 2026Article
- Review
- Molecular characterization of mixed-histology endometrial carcinoma provides prognostic and therapeutic value over morphologic findings.NPJ precision oncology · 2025Article
- The value of multi-sequence magnetic resonance imaging and whole-tumor apparent diffusion coefficient histogram analysis in differentiating p53 abnormal from non-p53 abnormal endometrial carcinoma.Frontiers in oncology · 2025Article
- Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.Frontiers in oncology · 2025Article
- Biomolecular Classification in Endometrial Cancer: Onset, Evolution, and Further Perspectives: A Critical Review.Cancers · 2024Review
- Determination of endometrial cancer molecular subtypes using a whole exome-sequencing based single-method approach.Journal of cancer research and clinical oncology · 2024Article
- Tailoring Endometrial Cancer Treatment Based on Molecular Pathology: Current Status and Possible Impacts on Systemic and Local Treatment.International journal of molecular sciences · 2024Review
- High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancer.Cellular oncology (Dordrecht, Netherlands) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 12 institutions in 1 country.
Funding
Abstract
objectivesThe purpose of this study was to assess the prognostic significance of a simplified, clinically accessible classification system for endometrioid endometrial cancers combining Lynch syndrome screening and molecular risk stratification.
methodsTumors from NRG/GOG GOG210 were evaluated for mismatch repair defects (MSI, MMR IHC, and MLH1 methylation), POLE mutations, and loss of heterozygosity. TP53 was evaluated in a subset of cases. Tumors were assigned to four molecular classes. Relationships between molecular classes and clinicopathologic variables were assessed using contingency tests and Cox proportional methods.
resultsMolecular classification was successful for 982 tumors. Based on the NCI consensus MSI panel assessing MSI and loss of heterozygosity combined with POLE testing, 49% of tumors were classified copy number stable (CNS), 39% MMR deficient, 8% copy number altered (CNA) and 4% POLE mutant. Cancer-specific mortality occurred in 5% of patients with CNS tumors; 2.6% with POLE tumors; 7.6% with MMR deficient tumors and 19% with CNA tumors. The CNA group had worse progression-free (HR 2.31, 95%CI 1.53-3.49) and cancer-specific survival (HR 3.95; 95%CI 2.10-7.44). The POLE group had improved outcomes, but the differences were not statistically significant. CNA class remained significant for cancer-specific survival (HR 2.11; 95%CI 1.04-4.26) in multivariable analysis. The CNA molecular class was associated with TP53 mutation and expression status.
conclusionsA simple molecular classification for endometrioid endometrial cancers that can be easily combined with Lynch syndrome screening provides important prognostic information. These findings support prospective clinical validation and further studies on the predictive value of a simplified molecular classification system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.